Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of food on abemaciclib tolerability in metastatic breast cancer
NCT03703466Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of abemaciclib in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants With Severe Diarrhea (>= Grade 3), Percentage of Participants With Prolonged Grade 2 Diarrhea and 4 more. Started Nov 2018; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03703466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703466.